CytoSorbents Corporation filed an 8-K on October 29, 2026, announcing it will report third quarter 2026 financial results and host a live investor webcast on November 12, 2026, after market close.

Key Highlights

  • Results date: Third quarter 2026 financial results will be released after market close on Thursday, November 12, 2026.
  • Webcast time: Management will host a live presentation and question-and-answer session starting at 4:30 PM ET on November 12, 2026.
  • Product reach: According to the filing, CytoSorb is approved in the European Union and distributed in over 70 countries worldwide, with more than 300,000 devices used cumulatively to date.
  • Regulatory designations: DrugSorb-ATR has received two FDA Breakthrough Device Designations, covering ticagrelor and the direct oral anticoagulants apixaban and rivaroxaban.
  • U.S. status: The filing states that CytoSorb is not yet approved or cleared in the United States, and DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.

CytoSorbents Schedules November 12 Earnings Event for Third Quarter 2026

CytoSorbents Corporation (NASDAQ:CTSO), which the filing describes as "a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification," announced that it will release its third quarter 2026 financial results after the market close on Thursday, November 12, 2026. The company's management team will then host a live webcast beginning at 4:30 PM ET the same day, including a question-and-answer session with participants. The filing recommends that attendees join approximately 10 minutes before the start of the call.

The filing provides context on the company's core technology, noting that CytoSorbents' "proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption." These cartridges, according to the filing, are compatible with standard blood pumps already in use at hospitals, including dialysis machines, continuous renal replacement therapy systems, extracorporeal membrane oxygenation equipment, and heart-lung machines.

The filing also highlights two primary applications of the technology: removal of blood thinners during and after cardiothoracic surgery to reduce severe bleeding risk, and removal of inflammatory agents and toxins in critical illnesses such as sepsis, burn injury, trauma, liver failure, and cytokine storm. The company's forward-looking statements, which it identifies as subject to cautionary language under the Private Securities Litigation Reform Act of 1995, reference goals including achieving "cash-flow break-even in the second half of 2026" and pursuing FDA marketing authorization for DrugSorb-ATR.

What Was Disclosed

CytoSorbents announced via an 8-K filed October 29, 2026, that it will report Q3 2026 results after market close on November 12, 2026, and host a live investor webcast with a question-and-answer session starting at 4:30 PM ET that day.